HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists

Moderna and Pfizer COVID-19 Vaccine 4X Price Increase Worries UK and US Lawmakers

As the COVID-19 pandemic inches closer to its endemic phase, Moderna and Pfizer are gearing up to nearly quadruple the price of their mRNA-based vaccines. This has drawn concern and ire from politicians in the UK and US, with four members of the UK Parliament penning a letter urging them to […]

more info 01/31/2023View Related Articles
Bookmark and Share

US Senators Blast Moderna for COVID Vaccine Price Hikes

Moderna is drawing heat from some US lawmakers and political leaders over its plans to spike prices of its COVID-19 vaccine to $110-130 per shot. The planned price hike, which is higher than the original price increases floated last fall, was lambasted by senators like Bernie Sanders (I-VT), […]

more info 01/27/2023View Related Articles
Bookmark and Share

Millions of Medicaid Beneficiaries Likely to Lose Coverage When Continuous Enrollment Ends

Medicaid enrollees must reapply every year in a complicated process fraught with hidden pitfalls that could sink one’s coverage. This process was suspended during the pandemic, but the provision’s end date of March 31st is fast approaching. As a result, millions of beneficiaries are set to lose […]

more info 01/26/2023View Related Articles
Bookmark and Share

Pfizer and China in Deadlock Over High Paxlovid Price Amid COVID Surge

As China struggles with a massive surge in cases following the end of its COVID Zero policy, the nation’s officials are at odds with Pfizer over the cost of its COVID-19 pill Paxlovid. Critics of big pharma argue that the middle of an outbreak is not the time to be playing hardball, but […]

more info 01/17/2023View Related Articles
Bookmark and Share

Moderna Eyes ~$120 COVID-19 Vaccine Price Tag

Moderna is looking to price its mRNA COVID-19 vaccine between $110 and $130 per shot, according Moderna CEO Stephane Bancel in an interview on Monday. The US government currently pays a discounted price of $26 per dose, but as the contract and the public health emergency comes to an end, most […]

more info 01/10/2023View Related Articles
Bookmark and Share

Report Finds Medicare Part B Lab Test Spending Jumped $1.3 Billion in 2021

A newly released report by the Office of the Inspector General (OIG) found that Medicare Part B spending on lab testing jumped by $1.3 billion in 2021 from 2020. This 17% increase brought the total spending on laboratory tests to $9.3 billion. A key driver of the spike comes from mass utilization of […]

more info 12/29/2022View Related Articles
Bookmark and Share

ICER Cuts Price Recommendation for Paxlovid

The Institute for Clinical and Economic Review has issued a change to its suggested US price for Paxlovid, Pfizer’s antiviral drug for COVID-19, dropping it to between $563 and $906. The institute formerly recommended a price range of $3,600 to $5,800 for a round of treatment. The change was made […]

more info 12/21/2022View Related Articles
Bookmark and Share

Real-World Data Shows Bivalent COVID-19 Boosters Reduce Hospitalizations and Urgent Care Utilization for Older Adults

Two recently published studies have found that inoculation with the new bivalent COVID-19 mRNA boosters by Moderna and Pfizer reduce the rate of hospitalization and urgent care visits. Older adults were particularly protected by the shots, which boasted an efficacy against hospitalization of 83% and […]

more info 12/19/2022View Related Articles
Bookmark and Share

EMA Emergency Task Force Recommends Bivalent COVID-19 Vaccines for Initial Inoculations

An Emergency Task Force (ETF) of the European Medicines Agency (EMA) has announced that it supports the use of bivalent mRNA COVID-19 vaccines for primary inoculations. The vaccines, which contain mRNA from the original SARS-CoV-2 and the Omicron BA.4/BA.5 strains, were previously only used as […]

more info 12/07/2022View Related Articles
Bookmark and Share

Real-World Data Study Supports Use of Paxlovid for COVID-19 in High-Risk Patients

A newly-published real-world study in the Journal of the American College of Clinical Pharmacy finds new data supporting the use of Paxlovid in high-risk COVID-19 patients. The retrospective study followed patients administered the combination therapy at a single medical center, finding that the […]

more info 11/28/2022View Related Articles
Bookmark and Share

  • 1
  • 2
  • 3
  • …
  • 51
  • Next Page

 

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

  • SQL Developer
  • Senior Research Consultant - Modelling and Meta Analysis
  • Research Consultant - Evidence Synthesis & Economic Modelling
  • Associate Director – Modelling & Meta-Analysis
  • Director, Real World Evidence
 
Syndicated Reports

Biotech R&D: a target-rich environment

Global Gene Therapy Report 2022-2031

ePrescribing Market – This is How Key Players are Dominating Global Industry

Health Economics and Outcomes Research (HEOR) Services Market to 2028

 
White Papers

Real World Evidence Solutions Global Market Report 2022

AI for Pharma and Biotech Market Pricing Strategy, Industry Latest News, Top Company Analysis, Research Report Analysis and Share by Forecast 2026

Whitepaper – Engaging the End Prescriber: A Practical Guide to Working With Physicians

Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines

HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Jobs
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists